Mainstay Medical has secured approval from the US Food and Drug Administration (FDA) for its ReActiv8 device, which is used to treat chronic back pain.
ReActiv8, which won European approval in 2016, is implanted in a surgical procedure and works by using electrical stimulus of nerves in muscles supporting the lower spine.
FDA approval is primarily based on results from a clinical study involving over 200 patients.
“This milestone is the culmination of a development process over many years,” said chief executive Jason Hannon.
FDA approval grants Mainstay the right to market ReActiv8 in the US as an aid in the management of intractable chronic low back pain associated with multifidus muscle dysfunction in adults who have failed therapy and are not candidates for spine surgery.
Mainstay, which is based in Dublin with subsidiaries in Australia, the United States and Germany, said it is currently refining its commercial launch plans for the US, including building out its commercial team in the region.
The company currently estimates that there are approximately two million people in the EU and the US who could be candidates for ReActiv8. It estimates the market for disabling chronic lower back pain in patients not suitable for surgery is worth approximately $30 billion.
Mainstay made its first commercial sale for ReActive8 in 2017 shortly after it won a CE mark, which authorises is sale across the EU. The product was this month approved for inclusion in a list which means it is eligible for reimbursement from all private health insurers in Australia
The company recently announced plans to take the listed company private due to a lack of liquidity in its shares and the costs associated with being publicly listed.
"device" - Google News
June 22, 2020 at 02:56PM
https://ift.tt/2YXswXx
Mainstay Medical gets approval to sell back pain device in US - The Irish Times
"device" - Google News
https://ift.tt/2KSbrrl
https://ift.tt/2YsSbsy
Bagikan Berita Ini
0 Response to "Mainstay Medical gets approval to sell back pain device in US - The Irish Times"
Post a Comment